![](https://2c717466dc25cd7041c9-8eeda6a8ca964cf210ed223dbc947813.ssl.cf2.rackcdn.com/18595033-653014704-akero-logo-with-white-space-1-jpg-100x56.jpeg)
Akero Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
-- Initiated Phase 3 SYNCHRONY Outcomes Trial of Lead Candidate Efruxifermin (EFX) in Patients with Compensated Cirrhosis (F4) Due to MASH -- Presented Poster and Late-breaking Oral Presentation on EFX at the EASL Congress 2024 -- -- Leadership Team …